Butyric Acid

Butyric Acid

SCHEMBL4169377

CCCC(=O)O.CN(C)S(=O)(=O)c1cc2c(cc1F)[nH]c(=O)c1[nH]ccc12

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
PARP1 P09874 2/20 0.32
IMPDH2 P12268 2/20 0.31
BRD9 Q9H8M2 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 3/20 0.31
MAPT P10636 1/20 0.31
SERPINE1 P05121 1/20 0.30
SCN9A Q15858 1/20 0.30
GAA P10253 1/20 0.30
MAPK1 P28482 1/20 0.30
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30
FFAR4 Q5NUL3 1/20 0.30
GRIN1 Q05586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4157908 0.90 KDM4E (0.34) KDM4EPARP1MEN1KMT2AGAA
Butyric Acid SCHEMBL4161012 0.89 ALDH1A1 (0.36) KDM4EKEAP1NFE2L2MEN1KMT2A
Butyric Acid SCHEMBL4162510 0.89 PKM (0.37) KDM4EPARP1MAPTGAA
Butyric Acid SCHEMBL4165214 0.86 ALOX5AP (0.36) MEN1KMT2AALOX5APFEN1
SCHEMBL4717471 0.79 BRD4 (0.33) KDM4EPARP1MEN1KMT2AALDH1A1
Butyric Acid SCHEMBL4171746 0.78 PKM (0.37) KDM4EKEAP1NFE2L2PARP1ALDH1A1
Butyric Acid SCHEMBL4171971 0.77 PKM (0.36) KDM4EKEAP1NFE2L2MEN1KMT2A
Butyric Acid SCHEMBL4169890 0.76 KDM4E (0.59) KDM4EKEAP1NFE2L2KMT2AALDH1A1
Propionic Acid SCHEMBL4162945 0.76 KDM4E (0.47) KDM4EKEAP1NFE2L2MEN1KMT2A
Butyric Acid SCHEMBL4163999 0.74 KDM4E (0.47) KDM4EMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885KEAP1 487/4885NFE2L2 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.